

Rural prioritization may increase the impact of COVID-19 vaccines in Sub-Saharan Africa due to ongoing internal migration: A modeling study

Prashanth Selvaraj^a, Bradley G. Wagner^a, Dennis L. Chao^a, Maïna L'Azou Jackson^b, J. Gabrielle Breugelmans^c, Nicholas Jackson^c, Stewart T. Chang^a

^a*Institute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, Washington, USA*

^b*Coalition for Epidemic Preparedness and Innovations, Oslo, Norway*

^c*Coalition for Epidemic Preparedness and Innovations, London, UK*

Abstract

How COVID-19 vaccine is distributed within low- and middle-income countries has received little attention outside of equity or logistical concerns but may ultimately affect campaign impact in terms of infections, severe cases, or deaths averted. In this study we examined whether subnational (urban-rural) prioritization may affect the cumulative two-year impact on disease transmission and burden of a vaccination campaign using an agent-based model of COVID-19 in a representative Sub-Saharan Africa country setting. We simulated a range of vaccination strategies that differed by urban-rural prioritization, age group prioritization, timing of introduction, and final coverage level. Urban prioritization averted more infections in only a narrow set of scenarios, when internal migration rates were low and vaccination was started by day 30 of an outbreak. Rural prioritization was the optimal strategy for all other scenarios, e.g., with higher internal migration rates or later start dates, due to the presence of a large immunological naive rural popula-

Preprint submitted to Lancet Global Health

June 19, 2021

tion. Among other factors, timing of the vaccination campaign was important to determining maximum impact, and delays as short as 30 days prevented larger campaigns from having the same impact as smaller campaigns that began earlier. The optimal age group for prioritization depended on choice of metric, as prioritizing older adults consistently averted more deaths across all of the scenarios. While guidelines exist for these latter factors, urban-rural allocation is an orthogonal factor that we predict to affect impact and warrants consideration as countries plan the scale-up of their vaccination campaigns.

Keywords: COVID-19, vaccination, urban/rural transmission, serology, sub-Saharan Africa, vaccination impact, low and middle income countries

1 Introduction

2 COVID-19 has presented every country with a challenge to formulate
3 a strategy to protect its population, initially with non-pharmaceutical in-
4 terventions (NPI)/public health and safety measures (PHSM) and more re-
5 cently vaccination. As of June 2021, the World Health Organization (WHO)
6 has granted Emergency Use Listing to five vaccines [1], though supplies are
7 expected to be limited, particularly in low- and middle-income countries
8 (LMIC). The COVID-19 Vaccines Global Access (COVAX) Advance Market
9 Commitment (AMC) is expected to be the primary mechanism by which
10 most of 92 eligible LMICs procure COVID-19 vaccines, beginning with 3%
11 population coverage for health care workers (HCW) and increasing to 20%
12 population coverage for the elderly and adults with comorbidities [2]. Previ-
13 ous modeling studies have indicated that prioritizing elderly adults for vac-

14 cination would yield the largest reductions in mortality [3, 4] given the steep
15 gradient of mortality observed with age in China, Europe, and other coun-
16 tries [5, 6]. Meanwhile, HCW have been prioritized to preserve health system
17 capacity [2].

18 How countries should allocate vaccines subnationally has received little
19 attention outside of equity or logistical considerations. While the WHO re-
20 quires countries to submit national deployment and vaccination plans (ND-
21 VPs) [7] prior to receiving vaccines from COVAX [8], WHO guidance on
22 developing NDVPs mentions geography only in the context of ensuring equi-
23 table access. In particular the guidance encourages countries to give special
24 consideration to “those living in informal settlements or urban slums... pop-
25 ulations in conflict settings or those affected by humanitarian emergencies,
26 and other hard-to-reach population groups” but does not explore the epi-
27 demiological impact of such policy decisions [7]. Likewise, WHO guidance
28 on logistics mentions “remote areas” but only with respect to the ultra-low
29 temperatures required to store certain vaccines and the need for special de-
30 vices such as thermal shippers with dry ice [9]. These documents highlight
31 the challenges that rural areas (and some urban areas) are expected to face
32 during COVID-19 vaccination campaigns and suggest that the default may
33 be to overlook these areas or distribute vaccine to these areas at a slower
34 pace.

35 In this study we ask whether urban or rural prioritization of COVID-19
36 vaccines may also affect the impact of the vaccination campaign on disease
37 burden. Using an agent-based model set in a representative Sub-Saharan
38 African (SSA) setting, we examine the possible impact on transmission and

39 disease burden of campaigns prioritizing urban or rural areas to receive vac-
40 cine first, while also accounting for other factors such as age group prior-
41 itization, variable dates of vaccine introduction, and final vaccine coverage
42 levels.

43 **Results**

44 *Ongoing migration generates multiple peaks in COVID-19 incidence at the*
45 *country level*

46 To explore possible COVID-19 trajectories in SSA, we created an agent-
47 based model of the spread of COVID-19 in a SSA-like country setting where
48 the population was split between urban and rural areas. The population
49 was assumed to be immunologically naive, and NPI/PHSM policies were
50 simulated as dynamic changes in transmission. Infections were seeded in the
51 urban node and allowed to spread to rural nodes through internal urban-rural
52 migration (Figure 1).

53 In the baseline scenario, moderate transmission and ongoing migration
54 ($R_0 = 2.4$, migration = 20 000 daily trips per million individuals, dtpmi)
55 resulted in separate incidence peaks in urban and rural areas which aggre-
56 gated to give two peaks at the country level (Figure 1, middle column, middle
57 row). Cases rose quickly in urban areas and more gradually in rural areas
58 with urban and rural peaks separated by approximately four months. After
59 two years, a majority of the overall population ($58\% \pm 2\%$) had been infected
60 at some point (Figure 2). A larger fraction of the urban population was ever
61 infected (81% cumulative urban infections vs. 48% cumulative rural infec-
62 tions), but rural infections outnumbered urban infections due to the larger




Figure 1: Daily COVID-19 incidence with varying transmission and migration in an archetypal SSA country setting. Urban and rural curves show new cases per day out of a population of 400 000 individuals split 40% urban and 60% rural. Peak percentages represent cumulative incidence as a percentage of the respective sub-population on the date when the highest incidence in each sub-population occurs indicated by the dashed vertical line. Time in days since first imported case. Low, medium, and high migration = 2000, 20 000, and 200 000 dtpmi, respectively.

63 rural population (Figure 2).

64 Using the baseline scenario as reference, we examined the effects of trans-
 65 mission and migration separately on the epidemic characteristics (Figure 1).




Figure 2: Cumulative COVID-19 incidence with varying transmission and migration in an archetypal SSA country. Urban and rural curves show percentage ever infected out of a population of 400 000 individuals split 40% urban and 60% rural. Peak percentages represent cumulative incidence as a percentage of the respective sub-population on the date when the highest incidence in each sub-population occurs indicated by the dashed vertical line. Time in days since first imported case. Low, medium, and high migration = 2000, 20 000, and 200 000 dtpmi, respectively.

66 Increasing the transmission rate (from $R_0 = 2.0$ to 2.8) while holding mi-
 67 gration constant shortened the time between urban and rural peaks (e.g.,

68 from 287 to 92 days when migration = 20 000 dtpmi, Figure 1). This also
69 resulted in a proportional increase in cumulative incidence as expected (Fig-
70 ure 2; however, other qualitative features such as the number of peaks at the
71 country level remained unchanged (Figure 1).

72 By comparison, increasing the internal migration rate while holding trans-
73 mission constant resulted in qualitative changes to the incidence curve includ-
74 ing the number of peaks at the country level (Figure 1). At medium rates of
75 migration (migration = 20 000 dtpmi), separate urban and rural peaks were
76 apparent at the country level with any level of transmission (Figure 1). In
77 this scenario, approximately equal numbers of cases came from urban and
78 rural areas (Figure 2). At low rates of migration (migration = 2000 dtpmi),
79 the outbreak was predominantly urban, with urban areas contributing the
80 majority of cases (Figure 2). Rural incidence failed to increase appreciably
81 but instead contributed to a long tail of declining incidence at the country
82 level (Figure 1). Conversely, at high rates of migration (migration = 200 000
83 dtpmi), a predominantly rural outbreak was observed, with rural areas con-
84 tributing the majority of cases (Figure 2). Incidence increased in both urban
85 and rural areas but continued increasing in rural areas even after starting to
86 decline in urban areas (Figure 1). Therefore, both low and high migration
87 rates tended to produce single-peak outbreaks, while intermediate migration
88 rates resulted in multiple peaks, marking the transition between between
89 predominantly urban and rural outbreaks.

90 At extreme values of transmission and migration, the model demonstrated
91 two contrasting outbreak scenarios. A more contained, primarily urban out-
92 break was generated when transmission and migration rates were low ($R_0 =$

93 2.0 and migration = 2000 dtpmi); cumulative incidence was 62% and 5% in
94 urban and rural areas, respectively, and $22\% \pm 2\%$ at the country level (Fig-
95 ure 2). A less contained, widespread outbreak was generated when transmis-
96 sion and migration rates were high ($R_0 = 2.8$ and migration = 200 000 dtpmi);
97 cumulative incidence was 78% and 63% in urban and rural areas, respectively,
98 and $68\% \pm 2\%$ at the country level (Figure 2). This range of cumulative in-
99 cidence was consistent with seroprevalence rates in SSA [10, 11, 12, 13, 14].

100 *Increasing coverage has a limited capacity to compensate for delays in COVID-*
101 *19 vaccine introduction*

102 To examine the effect of COVID-19 vaccination policies on population-
103 level impact, we simulated roll-out strategies that differed in several respects:
104 age prioritization (i.e., older or younger adults first), timing (start day) of vac-
105 cine introduction, final vaccine coverage level, and spatial prioritization (i.e.,
106 urban or rural areas first). Vaccines were assumed to be either acquisition-
107 blocking (preventing most infection after exposure) or disease-blocking (al-
108 lowing infection and limited transmission but preventing most disease). Im-
109 pact was evaluated on the basis of cumulative infections, severe cases, and
110 deaths averted after two years compared to a counterfactual baseline scenario
111 of moderate transmission and ongoing migration ($R_0 = 2.4$, migration = 20
112 000 dtpmi).

113 We first asked what effect age prioritization and timing of introduction
114 might have on vaccination impact (Figure 3). To simplify the analysis, we
115 fixed vaccine coverage at 50% and distributed vaccine to both urban and
116 rural areas with equal priority. We found that the optimal age prioritiza-
117 tion strategy depended on the choice of impact metric. Prioritizing younger

118 adults to receive an acquisition-blocking vaccine averted more infections than
119 prioritizing older adults or random distribution by age (e.g., $15\% \pm 3\%$ versus
120 $13\% \pm 2\%$ and $7\% \pm 2\%$, respectively, when introduced at day 60, Figure 3,
121 left column, top row), consistent with the large proportion of younger adults
122 in SSA populations ([15]) and degree of contact that occurs within this age
123 group ([16]). With a disease-blocking vaccine, prioritizing younger adults
124 continued to be more effective in averting infections than prioritizing older
125 adults, but the relative differences were reduced (Figure 3, left column, bot-
126 tom row).




Figure 3: Vaccination impact by age prioritization and timing of vaccine introduction. Age groups for prioritization were as follows: “old first” = beginning with adults age 70 years or older; “young first” = beginning with adults age 15–49 years; “random” = without prioritization (i.e., all ages have equal priority).

127 By comparison, prioritizing older adults was consistently more effective
128 at averting severe cases or deaths than prioritizing younger adults or random
129 distribution by age. For an acquisition-blocking vaccine, prioritizing older

130 adults averted approximately twice as many deaths as prioritizing younger
131 adults, regardless of date of introduction (Figure 3, right column, top row).
132 These differences were greater in magnitude for a disease-blocking vaccine
133 (Figure 3, right column, bottom row). Regardless of impact metrics, delays
134 in vaccine introduction reduced but did not negate the absolute differences
135 in impact between age prioritization strategies (Figure 3).

136 We then asked whether higher coverage levels could compensate for a
137 later date of introduction. In this case, we assumed priority would go to
138 older adults based on the deaths averted as a metric (Figure 4) and WHO
139 fair allocation guidelines [2]. Final coverage levels were varied between 20%
140 and 80% representing COVAX targets [2] and an optimistic scenario with ad-
141 ditional vaccine procurement, respectively. Regardless of metric (infections,
142 severe cases, or deaths averted) or start day of vaccination (30-180 days after
143 first case), increasing vaccination coverage also increased the impact (Fig-
144 ure 4).

145 The maximum possible impact for any given coverage level diminished
146 rapidly with delays in the start of vaccination (Figure 4). An optimistic
147 campaign with 80% coverage of an acquisition-blocking vaccine averted 16%
148 of infections when introduced on day 30 but only 2% of infections when
149 introduced on day 180. The impact of vaccination at other coverage levels was
150 similarly diminished by delays in introduction (Figure 4). As a result, higher
151 coverage levels were necessary for a campaign started later to have the same
152 impact as a campaign started earlier with lower coverage levels. In certain
153 cases, the gain from starting vaccination earlier could not be matched by
154 delayed vaccination, even with very high final coverage levels. For example,

155 to avert the same number of deaths (32% of baseline deaths) as a campaign
 156 started on day 30 with 30% coverage, a campaign started on day 90 would
 157 need to attain 80% coverage (Figure 4, right column, top row). However,
 158 campaigns started on day 30 with $\geq 60\%$ coverage resulted in levels of impact
 159 ($\geq 44\%$ of baseline deaths averted) that could not be achieved by campaigns
 160 started later, regardless of coverage level (examined up to 80% coverage)
 161 (Figure 4, right column, top row).




Figure 4: Vaccination campaign impacts by final coverage level and timing of vaccine introduction. Percentage reductions are shown for the respective cumulative indicator (infections, severe cases, or deaths) with respect to the baseline scenario without intervention.

162 Trends with respect to age prioritization, timing of introduction, and final
 163 coverage levels were robust to choice of baseline scenarios, including changing
 164 the level of transmission or ongoing migration (Supplementary Information).

165 *Rural prioritization optimizes vaccination in the presence of ongoing migra-*
166 *tion*

167 Finally we asked to what extent spatial (urban or rural) prioritization
168 could affect the impact of a COVID-19 vaccination campaign in an archety-
169 pal SSA setting. We again assumed that priority would be given to older
170 adults but that within each age tier, those in the prioritized spatial setting
171 would be vaccinated first. For example, for rural prioritization, we assumed
172 vaccine would go to rural individuals 70+ years, then urban 70+ years, ru-
173 ral 60-69 years, and so on. We also varied final coverage levels (20%, 50%,
174 or 80%), start dates of introduction (30, 90, or 180 days), and type of vac-
175 cine (acquisition- or disease-blocking). For our counterfactual, we assumed
176 a baseline of moderate transmission and ongoing migration ($R_0 = 2.4$, mi-
177 gration = 20 000 dtpmi) or the extremes of a more confined or less confined
178 outbreak ($R_0 = 2.0$, migration = 2000 dtpmi or $R_0 = 2.8$, migration = 200
179 000 trips dtpmi, respectively) (cf. Figures 1, 2).

180 For the majority of vaccination scenarios, we found that rural priori-
181 tization would avert more infections, severe cases, and deaths than urban
182 prioritization (Figure 5). Urban prioritization achieved greater impact for
183 a small set of conditions: when the outbreak was largely confined to urban
184 areas (with low transmission and low migration) and vaccination was started
185 early in the outbreak (by day 30) (Figure 5, left column). For all other sce-
186 narios, including those with higher transmission or migration, or campaigns
187 started at later dates, rural prioritization resulted in greater impact (Fig-
188 ure 5, center and right columns). These differences were most pronounced
189 when impact was measured by infections averted. For other metrics such as

190 severe cases (Figure 5, rows 2 and 5), the differences between urban and ru-
191 ral prioritization tended to be modest but still significant, e.g., with medium
192 transmission and migration ($R_0 = 2.4$, migration = 20 000 dtpmi, medium
193 migration). This was attributable to the prolonged spread of the epidemic in
194 such scenarios (Figure 1) as well as our assumption that age groups would be
195 given priority over spatial distribution such that in all scenarios in Figure 5,
196 older age groups were vaccinated first.

197 The acquisition-blocking vaccine had a higher impact on transmission
198 than the disease-blocking vaccine, particularly when impact was measured
199 by infections averted. However, differences in impact between the two vac-
200 cine types were strongly dependent on transmission trajectories over time,
201 coverage, and the start time of vaccine roll-out. In the low migration and low
202 transmission scenario ($R_0 = 2.0$, migration = 2000 dtpmi), the two vaccines
203 were largely similar. For example, for campaigns prioritizing urban areas
204 started on day 30, both vaccines had negligible effects on infections averted
205 with 20% final coverage. These differences increased to 7% of infections (10%
206 and 3% with acquisition- and disease-blocking, respectively) with 80% final
207 coverage (Figure 5, left column) and decreased with delays in the start date
208 of vaccine roll-out. When transmission and migration were both higher (R_0
209 = 2.4, migration = 20 000 dtpmi, medium migration), the epidemic per-
210 sisted longer (Figure 1), and larger magnitude differences between vaccine
211 types were observed. For campaigns prioritizing rural areas started on day
212 30, the difference between vaccine types was 3% of infections with 20% final
213 coverage and 15% of infections with 80% final coverage (Figure 5, middle
214 column). These modest absolute differences in impact were attributable to




Figure 5: Vaccination campaign impact on infections, severe cases and deaths by spatial (urban-rural) prioritization. Bars indicate mean reduction in respective cumulative indicator, and error bars indicate standard error.

215 the slow roll-out of vaccine over a 12-month period, particularly during the
216 first 9 months when <50% of the vaccine will have been distributed [17].

217 The differences between acquisition-blocking and disease-blocking vac-
218 cines were reduced when impact was measured by severe cases and deaths
219 (Figure 5). The acquisition-blocking vaccine resulted in 2-4% more severe
220 cases averted than the disease-blocking vaccine across transmission scenarios
221 due to the reduction in transmission (Figure 5, rows 2 and 5). However, the
222 difference between vaccine types was negligible for deaths averted (Figure 5,
223 rows 3 and 6). This was attributable to our assumption that both vaccines
224 provide protection against severe disease and deaths and that age groups
225 would be given priority over spatial distribution.

226 In all three transmission scenarios in Figure 5 as well as the remaining sce-
227 narios (Supplemental Information), increased NPI/PHSM that also reduced
228 migration maximized the impact of vaccination campaigns.

229 Discussion

230 By applying an agent-based model with discrete individuals, we found
231 that ongoing urban-rural migration has the potential to extend COVID-19
232 outbreaks in a SSA-like setting. With either low or high internal migration
233 rates, our model predicted that a single incidence peak at the country level
234 would follow introduction, predominated by cases in urban and rural areas,
235 respectively. However, with intermediate migration rates, our model pre-
236 dicted that an initial predominantly urban outbreak would be followed by a
237 second rural outbreak, resulting in two peaks and extending the duration of
238 the outbreak.

239 Each of these migration scenarios was in turn associated with a different
240 optimal vaccination strategy. When migration rates were low (whether due
241 to geography, NPI/PHSM, or other causes) and if the vaccine could be rolled
242 out quickly, the optimal strategy was to target urban areas, preventing the
243 predominantly urban outbreak. However, with higher rates of urban-rural
244 migration, targeting rural areas resulted in greater impact and was the opti-
245 mal strategy, consistent with the largely rural population in SSA. Delays in
246 vaccination also resulted in rural prioritization becoming the optimal strat-
247 egy, as urban areas experienced outbreaks faster than rural areas and a larger
248 proportion of the population resided in rural areas.

249 The differences in impact between urban and rural prioritization strate-
250 gies warrant consideration as countries begin vaccinating their populations in
251 larger numbers. We are not aware of any NDVPs (such as made available on
252 the WHO COVID-19 Partners Platform [18]) that distinguish between urban
253 and rural areas, though a few countries such as Mexico are reportedly prior-
254 itizing rural areas [19]. While WHO guidance on subnational allocation has
255 been limited to equity or logistical considerations, possible effects on impact
256 were not explored [7, 9, 8]. If resources are not intentionally directed to rural
257 areas, urban allocation is likely to be the default strategy throughout SSA
258 and other LMIC. For example, Ameyaw et al. examined Demographic and
259 Health Survey data from 2010-2018 and found that children in urban areas
260 were fully vaccinated at higher rates than their rural counterparts (by 53%
261 to 41%, respectively) [20]. While we do not consider other mitigating factors
262 such as the ease of distribution in urban areas, the question of whether to
263 vaccinate a larger, immunologically naive rural population or a smaller, pre-

264 viously exposed urban population encapsulates what we expect is a dilemma
265 that countries may be facing in the near future. In this study we found that
266 vaccinating rural areas may have benefits beyond equity.

267 Spatial prioritization complemented other strategies such as prioritizing
268 older adults, as recommended by official WHO guidance [2]. Prioritizing
269 younger adults with a vaccine effective against acquisition reduced the over-
270 all number of infections, but prioritizing older adults more greatly reduced
271 severe cases and deaths. The inability of prioritizing younger age groups to
272 prevent as many severe cases and deaths as prioritizing older age groups was
273 ultimately due to the anticipated slow roll-out of vaccine. This in turn reflects
274 current projections which foresee a 12-month roll-out to reach 20% coverage
275 that is back-loaded; approximately 50% of the available doses is expected to
276 come in the last three months [17]. This pace, even assuming coverage rates
277 >20%, make it difficult to achieve herd immunity fast enough to prevent
278 infections, severe cases, and deaths in older adults without direct targeting.
279 These results are consistent with other recent models on COVID-19 vaccine
280 impact [21, 4, 3].

281 Our model also supports the position that countries should begin their
282 vaccination campaigns as soon as possible. Campaigns that started later had
283 a limited capacity to make up for the delay in vaccination, even when higher
284 coverage levels were assumed. In many scenarios, larger campaigns that
285 started later resulted in more deaths than smaller campaigns that started
286 earlier. This supports the urgency to direct vaccine to SSA as quickly as
287 possible, a position espoused by COVAX [22], the African Union [23], and
288 civil society [24].

289 One question that we did not address directly is which scenario currently
290 best fits each country in SSA: which have high or low ongoing internal mi-
291 gration, or high or low transmission? Because both of these parameters are
292 abstracted in the model, we propose that a careful epidemiological assess-
293 ment would be needed for each country to measure the outcome of ongoing
294 migration if present: a high cumulative incidence in rural areas compared to
295 urban areas. For example, this might be accomplished through serosurveys
296 as in Niger State in Nigeria [12] or through genomic surveillance to track
297 variants as in South Africa [25], Nigeria [26], and Kenya [27]. Both studies
298 showed that infections spread from urban centers to rural areas and that ru-
299 ral areas were slower to see increases in incidence, consistent with a degree of
300 restricted migration. Both countries and others in SSA may still have large
301 immunologically naive populations in rural areas.

302 Our model was informed by a mix of historical data but plausibly rep-
303 resents a future scenario. For example, while almost all SSA countries saw
304 initial outbreaks during the year 2020, the example of Manaus, Brazil demon-
305 strates how new variants may evade even high levels of existing immunity
306 [28]. In such situations, future outbreaks may continue to resemble new
307 outbreaks, leading to successive almost-memoryless incidence peaks. In ad-
308 dition, the vaccine roll-out in SSA has been limited thus far, making our
309 assumption reasonable that future vaccinations will essentially be starting
310 anew. As of June 2021, the Africa CDC reported that less than 2% of mem-
311 ber country populations received at least one dose of any vaccine and less
312 than 0.5% have been fully vaccinated [29]. Therefore, variants and low ex-
313 isting vaccine-induced immunity suggest our model and other outbreak-type

314 models will continue to have relevance.

315 Our study had several limitations. As an abstraction of a SSA country
316 setting, our model represents an average in many respects: demographics
317 (ages, contact patterns, urban-rural localization), COVID-19 response (as
318 tracked by Oxford CGRT [30]), and a generic urban-seeded outbreak. This
319 abstraction represents a trade-off that allowed us to focus on outbreak scenar-
320 ios that may be applicable to many countries, though not precisely calibrated
321 to any particular country. Our model also had several parameters that were
322 abstractions of physical processes and not precisely matched to data. For ex-
323 ample, internal migration did not correspond to a particular indicator such as
324 mobile phone-based movement but represents an aggregate of this and other
325 factors contributing to net migration [31]. We also made several simplifying
326 assumptions on COVID-19 immunity and vaccines such as previous infection
327 leading to perfect immunity and optimistic vaccine characteristics such as
328 those based on mRNA vaccines [32, 33], as well as no opportunity for rein-
329 fection. We also did not explicitly account for any particular SARS-CoV-2
330 variants. However, by spanning a range of transmission rates, we accounted
331 for increased infectiousness expected of new variants. In this case, our se-
332 lected vaccine efficacy rates may represent best-case scenarios, with variants
333 further reducing the impact on infections, severe cases, and deaths.

334 In sum, our model supports the position that countries should consider
335 spatial prioritization among other factors when planning how to distribute
336 COVID-19 vaccine, particularly those in SSA where vaccine supplies are ex-
337 pected to be limited. These countries have an ongoing opportunity to adapt
338 their strategy and if necessary set up an infrastructure that allows vaccine

339 to be prioritized to maximize impact.

340 **Methods**

341 *Model structure and demographics*

342 COVID-19 transmission dynamics were simulated using EMOD, a soft-
343 ware platform for agent/individual-based epidemiological modeling of infec-
344 tious diseases [34]. EMOD was used to represent an archetypal country
345 in sub-Saharan Africa (SSA) [35] through demographics (age pyramid and
346 urban-rural population distribution), contact structure, and mobility pat-
347 terns. Demographics were represented by taking the mean of each five year
348 age bin from the population pyramids in the SSA region [36]. The urban-rural
349 distribution of the population was obtained from published UN estimates,
350 and the mean was taken for all countries in SSA [15] (Figure 10). Contact
351 structures for the same set of age bins and countries in urban and rural set-
352 tings were obtained from Prem et al. [16]. These matrices were available for
353 home, school, workplace, and community settings, and a simple mean was
354 taken across SSA countries. To obtain the total contact matrices, we multi-
355 plied the NPI policy effect from the Oxford COVID-19 Government Response
356 Tracker described below and then summed all four settings together. Mobil-
357 ity patterns represented the within-country movement of people as described
358 below. Baseline parameter values are provided in Table 1 except for contact
359 matrices which are provided in Supplemental Methods.

360 Individuals were created at model initialization and assigned (a) an age to
361 match the desired age distribution and (b) a node representing either urban
362 or rural settings to match the desired urban-rural population distribution.

363 In total the model contained 200 nodes with node₁ representing an urban
364 setting and node_{2..200} representing rural settings with the same population
365 sizes at initialization (Figure 6). The urban node accounted for 40% of
366 the total population, while the rural nodes accounted for the remaining 60%.
367 This node structure was chosen to represent an SSA country having a capital
368 city serving as the main hub of international traffic and rural areas whose
369 residents travel to the capital city and other rural towns. Migration between
370 urban and rural nodes and between rural nodes was represented as a change
371 in the node assignment of individuals. The probability of a change in node
372 was calculated as the product of a base rate and the population sizes of
373 each pair of nodes, i.e., using a gravity-based model (Figure 6). The base
374 migration rate was not known a priori, so a range of values were evaluated
375 spanning several orders of magnitude (Table 1). This rate and other rates
376 in the model were implemented as exponentially distributed waiting times
377 between random events. Other demographic processes such as births, non-
378 disease deaths, and migration to other countries were assumed negligible on
379 the timescale of the model. The model was run for a simulated 2-year (730
380 day) duration.

381 *COVID-19 epidemiology in the model*

382 We represented COVID-19 outbreaks where an infected case was intro-
383 duced into a population that did not have pre-existing immunity (as hap-
384 pened in year 2020) or where a new SARS-CoV-2 variant might be intro-
385 duced that completely evades existing immunity. Individuals (agents) were
386 assumed to be in one of the following states: susceptible, infected, or re-
387 moved (recovered or dead). Infected individuals were seeded in the urban




Figure 6: Model schematic showing sample node and migration. Infected individuals were seeded in the urban node and infection spread to rural nodes via urban-rural migration.

Symbol	Parameter	Units	Baseline value	Range	Reference
$S_{t=0}$	Initial susceptible prop	Percent	99.9	NA	NA
$I_{t=0}$	Initial infected prop	Percent	0.1	NA	NA
$R_{t=0}$	Initial removed prop	Percent	0	NA	NA
R_0	Base reproduction number	New infections / infected indiv	2.4	2.0 - 2.8	NA
NPI_t	NPI intensity effect	Unitless multiplier	Varies	0 - 100	[30]
γ	(Avg infec duration) ⁻¹	Days ⁻¹	14 ⁻¹	NA	[37]
VE_S	Vax effic vs infec	Scalar	0.95	{0.95, 0}	[32, 33]
VE_I	Vax effic vs trans	Scalar	0.3	{0, 0.7}	NA
VE_P	Vax effic vs progr	Scalar	1.0	{0, 1.0}	[32, 33]
P_{vac}	Final vax coverage	Percent	50	{20, 50, 80}	[2]
p_{rural}	Rural pop	Percent	60	NA	[15]
b	Baseline migration	Probability / time step	20 000 dtpmi	20 - 200 000 dtpmi	NA
N_{tot}	Model agents	Integer	4×10^5	NA	NA
n_{rural}	Rural nodes	Integer	199	NA	NA
n_{urban}	Urban nodes	Integer	1	NA	NA
t	Time step	Days	1	NA	NA

Table 1: Model parameters

388 node at multiple time points (Table 1) during the first 60 days after which
 389 no additional importations were assumed to occur due to suspension of air

390 travel. Susceptible individuals became infected at a rate proportional to a
391 baseline rate of transmission $R_0 I(t)/c_{i,j}\gamma$ where R_0 represents the base repro-
392 duction number of COVID-19 from literature (Table 1), $I(t)$ the number of
393 infected individuals in the same node, $c_{i,j}$ the mean contact rate of individ-
394 uals of age groups i and j , and $\gamma =$ mean infectious duration in the model.
395 $c_{i,j}$ was obtained from the age- and location-dependent contact rates from
396 Prem et al. [16] across settings and countries in SSA. Infected individuals
397 transitioned to the removed state with the sum rate of recovery and death,
398 i.e., the inverse of the total infectious duration. Removed individuals did
399 not return to the susceptible state which was equivalent to (a) births and
400 deaths being negligible on the timescale of the model and (b) recovered in-
401 dividuals having perfect immunity that did not wane on the timescale of the
402 model. Individual-level behaviors were also simulated to a limited extent:
403 10% of infected individuals were assumed to self-isolate which reduced their
404 contributions to transmission in their respective node by 80%.

405 *Country-level events and policies in the model*

406 To represent typical country-level policies to outbreaks, we included a
407 quantification of NPI/PHSM policy strengths implemented in SSA since early
408 2020. We obtained data from the Oxford COVID-19 Government Response
409 Tracker (OxCGRT) Containment and Health Index which is the average of
410 14 sub-indexed indicators ranging between 0 and 100 where each sub-index
411 rates a specific type of policy on each day [30]. Dates in OxCGRT were
412 re-scaled to the date since first case reported to the WHO ([38], Table 2).
413 To derive a mean value for SSA, we used the mean NPI_t across countries
414 in SSA for each date since respective first case 7. $(1 - NPI_t/100)$ was used

415 as a contact rate multiplier for work and community settings. The school
416 settings was assumed to be closed (i.e., with $NPI_t = 100$) for 135 days
417 after first reported case then reopened with the same contact rate multiplier
418 as work and community settings. The home setting was assumed to have
419 increased contact rates by 25% (i.e., with $NPI_t = -25$). After the last day
420 of available NPI_t data, work, school, and community settings were assumed
421 to be opened to 75% of pre-COVID levels (i.e., with $NPI_t = 25$) to simulate
422 near-complete reopening in most SSA countries. We used the same multiplier
423 $(1 - NPI_t/100)$ on migration between all spatial nodes in the simulation to
424 account for changes in migration because of NPI policies.

Calendar day	Epidemic day (t)	Event or policy
15	-60	Importations begin
75	0	Earliest policies (assumed first reported case)
90	15	Importations stop
105 – 255	30 – 180	Vaccinations begin
210	135	Schools reopen

Table 2: Summary of events and policy implementation dates in model. Calendar day 0 = January 1, 2020

425 *Vaccination in the model*

426 COVID-19 vaccines in the model were represented as protecting individ-
427 uals by one of the following mechanisms:

- 428 1. Acquisition-blocking: preventing susceptible individuals from becoming
429 infected (called efficacy against susceptibility, VE_S in the biostatistical
430 literature [39])
- 431 2. Transmission-blocking: preventing shedding of infectious particles after
432 infection (efficacy against infectiousness, VE_I , in the literature [39])




Figure 7: NPI policies as scored by OxCGRT for SSA countries

433 3. Disease-blocking: preventing individuals from developing symptomatic
434 disease (efficacy against symptomatic illness, VE_P , in the literature
435 [39])

436 We assumed that vaccines would be highly efficacious and comparable to
437 the Pfizer/BioNTech or Moderna mRNA vaccines with $>90\%$ clinical trial
438 efficacy and effectiveness [32, 33]. We also made the simplifying assumption
439 that observed efficacy VE_{obs} was entirely attributable to either VE_S or VE_I
440 (see 1). That is, for an acquisition-blocking vaccine, we assumed $VE_S =$
441 VE_{obs} and $VE_P = 1$ resulting in all of the vaccinated individuals being
442 protected from disease progression despite infection. For a disease-blocking

443 vaccine, we assumed $VE_I = VE_{obs}$, $VE_P = 1$, again resulting in all of
444 the vaccinated individuals being protected from disease progression, even
445 if infected. Thus all vaccines, regardless of type, were assumed to prevent
446 severe disease and mortality. In the case of vaccines with lower efficacy, the
447 preventive effect on severe disease and deaths is also assumed to decrease
448 linearly. Finally, as our focus was on factors under the control of country
449 policymakers, we did not explicitly model SARS-CoV-2 variants or their
450 impact on vaccine efficacy. However, we expect that variants would have the
451 net effect of reducing impact similar to reduced coverage levels.

452 Vaccine availability followed the COVAX projections of vaccine supply
453 available from GAVI [17]. Briefly these projections assume vaccine will be-
454 come increasingly available over a period of 12 months until reaching a final
455 vaccination population coverage of $P_{vac} = 20\%$ or greater (Table 1).

456 Different age prioritization schemes were assumed to be available: oldest
457 first (in order: 70+ years, 60-69, 50-59, and 15-49), youngest first (in order:
458 15-49 years, 50-59, 60-69, and 70+), or random (all ages at the same time)
459 (Figure 9). Likewise, different spatial allocation schemes were assumed vi-
460 able: urban first, rural first, or random (equal priority to urban and rural ar-
461 eas) (Figure 9). Under random spatial prioritization, vaccine was distributed
462 to urban and rural nodes at a rate proportional to population size, e.g., at 1%
463 coverage, both 1% of the urban population and 1% of the rural population
464 would be covered. In the case of both age and spatial prioritization, age was
465 assumed to take precedence before spatial (urban, rural) setting.

466 At the individual (agent) level, if an individual was selected to receive a
467 vaccine, each dose was assumed to confer an increasing level of protection

468 until the level of protection specified by VE_S , VE_I , or VE_P was attained
469 (Figure 8). This profile was chosen to reflect the Moderna scheduling of
470 28 days between first and second doses [33]. Individual efficacy (regardless
471 of type) was assumed to begin at 0% on day 0 and increase linearly until
472 reaching 80% of final efficacy on day 10. This was maintained until day
473 28 when a second dose was assumed administered, then efficacy increased
474 linearly until final efficacy was reached on day 35. We assumed that all
475 individuals selected for vaccination would receive both vaccine doses and
476 that individual protection would not wane on the timescale of the model.
477 Vaccination scenarios in the model used the same random number draws as
478 baseline scenarios so that the individual- and population-level characteristics
479 were the same until the vaccination campaign began. Each scenario was
480 run with 40 realizations to derive mean and standard deviation of summary
481 statistics.




Figure 8: Ramp-up of protective effect within a vaccinated individual in the model




Figure 9: Vaccine allocation scenarios by spatial prioritization, age group, and month

482 *Parameter ranges for scenarios*

483 We evaluated vaccine distribution scenarios over a range of base trans-
 484 mission intensities represented by R_0 and migration rates. In the scenarios
 485 presented, R_0 varied between 2.0 to 2.8. Migration varied from a scenario
 486 where simulated agents make 2000 daily trips per million individuals (dtpmi)

487 under unmitigated (no NPI/PHSM) conditions to a high migration scenario
488 where 200 000 trips are completed each day.

489 With respect to vaccine distribution, we evaluated different final coverage
490 levels and vaccine distribution start times in addition to different age and
491 spatial prioritization strategies in urban and rural areas. Coverage levels were
492 varied from 20%-80% of the total population, while start times were varied
493 between 30-180 days after the first case. While the same start times were used
494 across different transmission scenarios, the number of infected individuals
495 varied depending on transmission intensity preceding the start of vaccine
496 distribution. Vaccine distribution start times could thus be considered a
497 proxy for different levels of population immunity at the start of a vaccination
498 campaign.

499 Contact structure, age pyramid, and government response tracker data
500 were available for 37 countries in sub-Saharan Africa, and all 37 countries
501 (shown in Figure 10) were used to develop a representative SSA country. A
502 full list of countries is available upon request.

503 **Acknowledgments**

504 The authors would like to thank Jonathan Bloedow and Christopher Lor-
505 ton from the Bill and Melinda Gates Foundation for software support and
506 Bob Small and Amol Chaudhari from the Coalition for Epidemic Prepared-
507 ness Innovations and the WHO SAGE Working Group on Covid-19 Vaccines
508 for informative discussions. This publication is based on research conducted
509 by the Institute for Disease Modeling at the Bill and Melinda Gates Foun-
510 dation. No external funding was involved.




Figure 10: Sub-Saharan African countries that were aggregated to form a representative country.

511 **Supporting information**

512 Supplementary figures: `Supplementary_figures.pdf`.

513 All code to reproduce the modeling results are available on Github or by
514 request to the authors.

515 **Author contributions statement**

516 P.S., B.W., D.L.C., and S.C. conceived the model scenarios. P.S. designed
517 and implemented the model and generated model outputs. S.C. and P.S.

518 wrote the manuscript. All authors reviewed the manuscript.

519 **References**

- 520 [1] World Health Organization. Status of COVID-19 Vac-
521 cines within WHO EUL/PQ evaluation process. Geneva:
522 World Health Organization; 2021. Available from: [https://extranet.who.int/pqweb/key-resources/documents/
523 status-covid-19-vaccines-within-who-eulpq-evaluation-process.](https://extranet.who.int/pqweb/key-resources/documents/status-covid-19-vaccines-within-who-eulpq-evaluation-process)
- 525 [2] Fair allocation mechanism for COVID-19 vaccines
526 through the COVAX Facility; 2021. Available
527 from: [https://www.who.int/publications/m/item/
528 fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility.](https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility)
- 529 [3] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad
530 YH, et al. Model-informed COVID-19 vaccine prioritization strate-
531 gies by age and serostatus. *Science*. 2021 Feb 26;371(6532):916–921.
532 doi:10.1126/science.abe6959.
- 533 [4] Hogan AB, Winskill P, Watson OJ, Walker PGT, Whittaker C, Baguelin
534 M, et al. Within-country age-based prioritisation, global allocation,
535 and public health impact of a vaccine against SARS-CoV-2: A math-
536 ematical modelling analysis. *Vaccine*. 2021 May 21;39(22):2995–3006.
537 doi:10.1016/j.vaccine.2021.04.002.
- 538 [5] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N,
539 et al. Estimates of the severity of coronavirus disease 2019: a model-

- 540 based analysis. *The Lancet Infectious Diseases*. 2020 Jun;20(6):669–677.
541 doi:10.1016/S1473-3099(20)30243-7.
- 542 [6] Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP,
543 Meyerowitz-Katz G. Assessing the age specificity of infection fatality
544 rates for COVID-19: systematic review, meta-analysis, and public policy
545 implications. *European Journal of Epidemiology*. 2020 Dec;35(12):1123–
546 1138. doi:10.1007/s10654-020-00698-1.
- 547 [7] Guidance on developing a national deployment and vaccination plan for
548 COVID-19 vaccines. Geneva: World Health Organization; 2021. Avail-
549 able from: [https://www.who.int/publications-detail-redirect/
550 WHO-2019-nCoV-Vaccine_deployment-2020.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Vaccine_deployment-2020.1).
- 551 [8] COVID-19 national deployment and vaccination plan: Submission
552 and review process, 29 January 2021. Geneva: World Health
553 Organization; 2021. Available from: [https://www.who.int/
554 publications-detail-redirect/WHO-2019-nCoV-NDVP-country_
555 plans-2021.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-NDVP-country_plans-2021.1).
- 556 [9] COVID-19 vaccination: supply and logistics guidance.
557 Geneva: World Health Organization; 2021. Available from:
558 [https://www.who.int/publications-detail-redirect/
559 who-2019-ncov-vaccine-deployment-logistics-2021-1](https://www.who.int/publications-detail-redirect/who-2019-ncov-vaccine-deployment-logistics-2021-1).
- 560 [10] Milleliri JM, Coulibaly D, Nyobe B, Rey JL, Lamontagne F, Hocqueloux
561 L, et al. SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Sur-

- 562 vey among Gold Mine Workers. *American Journal of Tropical Medicine*
563 *and Hygiene*. 2021;104(5). doi:10.4269/ajtmh.21-0081.
- 564 [11] Milleliri JM, Coulibaly D, Nyobe B, Rey JL, Lamontagne F, Hoc-
565 queloux L, et al. Seroprevalence of anti-SARS-CoV-2 IgG anti-
566 bodies among truck drivers and assistants in Kenya. medRxiv.
567 2021;doi:10.1101/2021.02.12.21251294v1.
- 568 [12] Majiya H, Aliyu-Paiko M, Balogu V, Musa D, Salihu I, Kawu A,
569 et al. Seroprevalence of COVID-19 in Niger State. medRxiv.
570 2020;doi:10.1101/2020.08.04.20168112.
- 571 [13] Mukwege D, Byabene AK, Akonkwa EM, Dahma H, Dauby N,
572 Buhendwa JPC, et al. High SARS-CoV-2 Seroprevalence in Health-
573 care Workers in Bukavu, Eastern Democratic Republic of Congo. *Am J*
574 *Trop Med Hyg*. 2021;104(4):1526–1530. doi:10.4269/ajtmh.20-1526.
- 575 [14] Sykes W, Mhlanga L, Swanevelder R, Glatt TN, Grebe E, Coleman C,
576 et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in
577 Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces
578 of South Africa in January 2021. *Res Sq*. 2021;doi:10.21203/rs.3.rs-
579 233375/v1.
- 580 [15] United Nations, Department of Economic and Social Affairs, Popula-
581 tion Division. *World urbanization prospects: the 2018 revision*. United
582 Nations; 2019. OCLC: 1120698127.
- 583 [16] Prem K, van Zandvoort K, Klepac P, Eggo RM, Davies NG, Cook AR,
584 et al. Projecting contact matrices in 177 geographical regions: an update

585 and comparison with empirical data for the COVID-19 era. medRxiv.
586 2021;doi:<https://doi.org/10.1101/2020.07.22.20159772>.

587 [17] COVAX Global Supply Forecast;. Available from: <https://www.gavi.org/news/document-library/covax-global-supply-forecast>.

589 [18] COVID-19 Partners Platform;. Available from: <https://covid19partnersplatform.who.int/en/pillar10>.

591 [19] Mexico is vaccinating its poorest citizens first – against the
592 advice of health experts. Washington Post. 2021;Available
593 from: https://www.washingtonpost.com/world/the_americas/mexico-coronavirus-vaccine-lopez-obrador/2021/02/25/81c28c50-76ad-11eb-9537-496158cc5fd9_story.html.

596 [20] Ameyaw EK, Kareem YO, Ahinkorah BO, Seidu AA, Yaya S. Decom-
597 posing the rural–urban gap in factors associated with childhood immu-
598 nisation in sub-Saharan Africa: evidence from surveys in 23 countries.
599 BMJ Global Health. 2021 Jan;6(1):e003773. Available from: <https://gh.bmj.com/content/6/1/e003773>. doi:10.1136/bmjgh-2020-003773.

601 [21] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization
602 for COVID-19: Who to vaccinate first? Sci Adv. 2020 Feb;7(6).
603 doi:10.1126/sciadv.abf1374.


604 [22] COVAX Joint Statement: Call to action to equip
605 COVAX to deliver 2 billion doses in 2021;. Avail-
606 able from: <https://www.who.int/news/item/27-05-2021-covax-joint-statement-call-to-action-to-equip-covax-to-deliver-2-b>

- 608 [23] Communique of the High-Level Emergency Virtual Meeting of
609 African Ministers of Health On the COVID-19 situation in
610 Africa;. Available from: [https://africacdc.org/news-item/
611 communique-of-the-high-level-emergency-virtual-meeting-of-african-ministers-o](https://africacdc.org/news-item/communique-of-the-high-level-emergency-virtual-meeting-of-african-ministers-o)
- 612 [24] Civil society to World Bank: Help us hold governments ac-
613 countable in COVID-19 vaccine distribution; 2021. Avail-
614 able from: [https://www.devex.com/news/sponsored/
615 civil-society-to-world-bank-help-us-hold-governments-accountable-in-covid-19-](https://www.devex.com/news/sponsored/civil-society-to-world-bank-help-us-hold-governments-accountable-in-covid-19-)
- 616 [25] Happi AN, Ugwu CA, Happi CT. Tracking the emergence of
617 new SARS-CoV-2 variants in South Africa. *Nature Medicine*.
618 2021 Mar;27(3):372–373. Available from: [https://www.nature.com/
619 articles/s41591-021-01265-1](https://www.nature.com/articles/s41591-021-01265-1). doi:10.1038/s41591-021-01265-1.
- 620 [26] Happi C, Ihekweazu C, Oluniyi PE, Olawoye I. SARS-CoV-2 genomes
621 from Nigeria reveal community transmission, multiple virus lineages
622 and spike protein mutation associated with higher transmission and
623 pathogenicity. 2020;. Available from: [https://virological.org/t/
624 sars-cov-2-genomes-from-nigeria-reveal-community-transmission-multiple-virus-
625 494.](https://virological.org/t/sars-cov-2-genomes-from-nigeria-reveal-community-transmission-multiple-virus-)
- 626 [27] Githinji G. Introduction and local transmission of SARS-CoV-
627 2 cases in Kenya;. Available from: [https://virological.org/t/
628 introduction-and-local-transmission-of-sars-cov-2-cases-in-kenya/
629 497.](https://virological.org/t/introduction-and-local-transmission-of-sars-cov-2-cases-in-kenya/)
- 630 [28] Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE,

- 631 Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, de-
632 spite high seroprevalence. *The Lancet*. 2021 Feb;397(10273):452–
633 455. Available from: [https://www.thelancet.com/journals/lancet/
634 article/PIIS0140-6736\(21\)00183-5/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00183-5/abstract). doi:10.1016/S0140-
635 6736(21)00183-5.
- 636 [29] COVID-19 Vaccination;. Available from: [https://africacdc.org/
637 covid-19-vaccination/](https://africacdc.org/covid-19-vaccination/).
- 638 [30] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID-
639 19 Government Response Tracker. Blavatnik School of Govern-
640 ment; 2020. Available from: [https://www.bsg.ox.ac.uk/research/
641 research-projects/covid-19-government-response-tracker](https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker).
- 642 [31] Grantz KH, Meredith HR, Cummings DAT, Metcalf CJE, Grenfell
643 BT, Giles JR, et al. The use of mobile phone data to inform anal-
644 ysis of COVID-19 pandemic epidemiology. *Nat Commun*. 2020 Sep
645 30;11(1):4961. doi:10.1038/s41467-020-18190-5.
- 646 [32] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lock-
647 hart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
648 Vaccine. *New England Journal of Medicine*. 2020 Dec;383(27):2603–
649 2615. Available from: <https://doi.org/10.1056/NEJMoa2034577>.
650 doi:10.1056/NEJMoa2034577.
- 651 [33] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak
652 R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
653 Vaccine. *New England Journal of Medicine*. 2021 Feb;384(5):403–

- 654 416. Available from: <https://doi.org/10.1056/NEJMoa2035389>.
655 [doi:10.1056/NEJMoa2035389](https://doi.org/10.1056/NEJMoa2035389).
- 656 [34] Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker
657 RS, et al. Implementation and applications of EMOD, an individual-
658 based multi-disease modeling platform. *Pathog Dis*. 2018;76(5):fty059.
659 [doi:10.1093/femspd/fty059](https://doi.org/10.1093/femspd/fty059).
- 660 [35] About Africa; 2021. Available from: [https://www.africa.undp.org/
661 content/rba/en/home/regioninfo.html](https://www.africa.undp.org/content/rba/en/home/regioninfo.html).
- 662 [36] World Population Prospects - Population Division - United Nations;
663 2021. Available from: [https://population.un.org/wpp/Download/
664 Standard/Population/](https://population.un.org/wpp/Download/Standard/Population/).
- 665 [37] Ali ST, Wang L, Lau EHY, Xu XK, Du Z, Wu Y, et al. Se-
666 rial interval of SARS-CoV-2 was shortened over time by nonphar-
667 maceutical interventions. *Science*. 2020 Aug 28;369(6507):1106–1109.
668 [doi:10.1126/science.abc9004](https://doi.org/10.1126/science.abc9004).
- 669 [38] WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Or-
670 ganization; 2021. Available from: <https://covid19.who.int/info/>.
- 671 [39] Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating in-
672 fluenza vaccine efficacy from challenge and community-based study
673 data. *American Journal of Epidemiology*. 2008 Dec;168(12):1343–1352.
674 [doi:10.1093/aje/kwn259](https://doi.org/10.1093/aje/kwn259).

Government response to COVID-19 in SSA countries



Country



Urban




Rural 1






Rural 2




Rural 3



Cumulative fraction of final vaccine allocation





Urban Rural

Start Day
30 90 180

16.0	11.0	7.0	5.0	3.0	2.0
13.0	9.0	7.0	4.0	3.0	2.0
11.0	7.0	6.0	4.0	3.0	2.0
8.0	6.0	5.0	3.0	2.0	1.0
6.0	5.0	3.0	3.0	1.0	1.0
4.0	3.0	2.0	2.0	1.0	1.0
2.0	2.0	2.0	1.0	1.0	-0.0

36.0	28.0	20.0	16.0	11.0	8.0
33.0	25.0	20.0	14.0	11.0	7.0
30.0	23.0	18.0	14.0	10.0	6.0
26.0	20.0	16.0	11.0	8.0	5.0
22.0	17.0	13.0	9.0	7.0	4.0
17.0	13.0	10.0	7.0	5.0	3.0
12.0	10.0	7.0	5.0	4.0	2.0


51.0	41.0	33.0	26.0	19.0	14.0
47.0	38.0	32.0	24.0	18.0	12.0
44.0	36.0	30.0	23.0	17.0	11.0
41.0	34.0	26.0	20.0	15.0	10.0
37.0	29.0	23.0	17.0	12.0	8.0
33.0	24.0	19.0	14.0	10.0	7.0
23.0	19.0	14.0	11.0	8.0	5.0










4.0	4.0	2.0	2.0	2.0	1.0
4.0	3.0	2.0	2.0	1.0	1.0
3.0	2.0	2.0	1.0	1.0	1.0
2.0	2.0	1.0	1.0	1.0	1.0
1.0	1.0	1.0	1.0	1.0	-0.0
1.0	1.0	1.0	1.0	1.0	-0.0
1.0	1.0	1.0	1.0	1.0	-0.0

33.0	27.0	20.0	15.0	11.0	7.0
30.0	24.0	18.0	14.0	10.0	6.0
28.0	21.0	16.0	12.0	9.0	6.0
23.0	19.0	14.0	11.0	8.0	5.0
20.0	16.0	12.0	9.0	7.0	4.0
16.0	13.0	9.0	7.0	5.0	3.0
12.0	9.0	6.0	5.0	4.0	2.0









51.0	42.0	33.0	26.0	20.0	13.0
48.0	40.0	32.0	25.0	18.0	12.0
47.0	38.0	29.0	23.0	17.0	11.0
40.0	34.0	25.0	20.0	15.0	10.0
36.0	31.0	24.0	17.0	13.0	8.0
31.0	24.0	20.0	16.0	10.0	7.0
24.0	18.0	14.0	10.0	8.0	5.0







Total
 Urban
 Rural



Prioritizing distribution by age

